Gujarat Themis Biosyn Share Price Today | Stock Price & Gujarat Themis Biosyn Share Screener
As of October 5, 2026, the live Gujarat Themis Biosyn share price (NSE: GUJTHEM) is ₹373.60 on NSE and ₹373.00 on BSE, down 2.15% from the previous close, with shares trading between ₹371.20 and ₹390.40 in today's trading session, and a 52-week range of ₹226.90–₹469.90. Check GUJTHEM price range for the annual price range and momentum. Use the Gujarat Themis Biosyn stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Gujarat Themis Biosyn opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹45 and net income of ₹11, with EBITDA of ₹20, an operating margin of 44.0% and a profit margin of 24.4%.
Gujarat Themis Biosyn Share Price Chart
Track the current stock price of Gujarat Themis Biosyn with an interactive chart. Analyse GUJTHEM share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Gujarat Themis Biosyn stock quote in one place.
The quote of ₹373.60 sits between the 52-week low of ₹226.90 and the 52-week high of ₹469.90, and the latest session moved -2.15% from the previous close.
Gujarat Themis Biosyn Company Profile - Fundamental Screener
Screen Gujarat Themis Biosyn company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for GUJTHEM shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE942C01045.
Company Details
Classification
Identifiers and Leadership
Gujarat Themis Biosyn Balance Sheet Screener
Screen GUJTHEM balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹503, up from ₹301 in 2025.
Latest statistics put total assets at ₹503 and shareholder funds at ₹288, with a leverage ratio of 0.36.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 503 | 301 | 221 | 166 | 123 | 88 | 64 | 33 | 21 | 21 |
| Current Assets | 89 | 52 | 48 | 62 | 78 | 63 | 29 | 8 | 8 | 8 |
| Fixed Assets | 289 | 41 | 38 | 33 | 19 | 19 | 17 | 15 | 11 | 11 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 137 | 32 | 4 | 2 | 2 | 3 | 5 | 1 | 1 | 1 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 288 | 248 | 201 | 149 | 103 | 70 | 42 | 19 | 12 | 8 |
| Share Capital | 11 | 11 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 |
| Reserves & Surplus | 277 | 238 | 194 | 142 | 96 | 63 | 35 | 11 | 5 | 1 |
Gujarat Themis Biosyn Income Statement Screener - Profit & Revenue Analysis
Screen Gujarat Themis Biosyn income statement and profit fundamentals. Analyze GUJTHEM quarterly results. Gujarat Themis Biosyn reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Mar, revenue was ₹45 and net profit was ₹11, equal to earnings per unit of ₹1.00, at an operating margin of 44%.
In that period expenses were ₹25, interest cost ₹2 and tax ₹3. The next period listed, 2026-Jun, shows revenue of ₹44 and net profit of ₹11.
| Item | 2026-Mar | 2026-Jun | 2025-Jun |
|---|---|---|---|
Revenue and Expenses | |||
| Revenue | 45 | 44 | 36 |
| Expenses | 25 | 23 | 22 |
Operating Costs and Margins | |||
| EBITDA | 20 | 21 | 14 |
| Operating Profit % | 44.00% | 47.00% | 39.00% |
| Depreciation | 4 | 4 | 2 |
| Interest | 2 | 2 | 0 |
Profit and Earnings | |||
| Profit Before Tax | 14 | 15 | 12 |
| Tax | 3 | 4 | 3 |
| Net Profit | 11 | 11 | 9 |
| EPS | 1.00 | 1.02 | 0.83 |
Gujarat Themis Biosyn Cash Flow Screener - Liquidity Fundamentals
Screen GUJTHEM cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹49, and net cash flow was an outflow of ₹9.
Over the same period, investing activities used ₹172 and financing activities provided ₹115.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 49 | 91 | 64 | 40 | 40 | 11 | 1 | 1 | 6 | 3 |
| Investing Activities | -172 | -112 | -55 | -20 | -30 | -2 | -3 | -6 | -1 | -3 |
Financing and Net Cash | ||||||||||
| Financing Activities | 115 | 26 | -9 | -13 | -14 | -5 | 2 | 5 | -4 | 0 |
| Net Cash Flow | -9 | 5 | 0 | 6 | -4 | 3 | 0 | 0 | 1 | 0 |
Gujarat Themis Biosyn Shareholding Pattern Screener
See Gujarat Themis Biosyn shareholding pattern with promoter, FII, and DII holdings. Check Gujarat Themis Biosyn promoter holding and ownership changes for GUJTHEM on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 70.86%, foreign institutions 1.80%, domestic institutions 1.18% and the public 19.88%, spread across 26,886 shareholders.
The shareholder count was 26,886 in 2026-Mar, compared with 27,010 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2026-Aug | 2025-Feb | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 70.86% | 70.86% | 59.33% | 70.86% | 70.86% | 70.86% | 70.86% | 70.86% |
Institutional Investors | ||||||||
| FII Holding | 1.80% | 1.77% | 4.93% | 0.00% | 1.91% | 2.51% | 2.95% | 1.96% |
| DII Holding | 1.18% | 1.18% | 13.79% | 1.16% | 1.17% | 1.17% | 1.17% | 1.17% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 19.88% | 19.46% | 16.43% | 19.75% | 19.66% | 19.31% | 18.72% | 19.90% |
| Other Holding | 6.28% | 6.73% | 5.52% | 8.22% | 6.39% | 6.14% | 6.29% | 6.10% |
| Shareholder Count | 26,886 | 27,010 | 26,899 | 30,695 | 30,673 | 28,945 | 28,319 | 27,325 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Gujarat Themis Biosyn. Gujarat Themis Biosyn dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹0.67 per unit for 2026-March, a yield of 0.18%, compared with ₹0.67 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹0.67, ₹0.67 and ₹1.00 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.67 | 0.18% |
| 2025-March | ₹0.67 | 0.30% |
| 2024-March | ₹1.00 | 0.35% |
| 2023-March | ₹5.40 | 2.04% |
| 2022-March | ₹11.00 | 12.02% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹1.65 | 6.08% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Gujarat Themis Biosyn Stock Index Membership - Nifty & Sensex
See which indices include Gujarat Themis Biosyn stock. Check GUJTHEM index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
The company is listed in 2 indices, including BSE INDEX BSE HC.
Among the benchmarks tracked are BSE INDEX BSE HC, BSE INDEX SMLCAP.
Complete Index List
Gujarat Themis Biosyn Market Events Screener - Corporate Actions
Get Gujarat Themis Biosyn corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Gujarat Themis Biosyn stock events that may affect GUJTHEM share price, along with derivatives, futures and options activity and sector gainers.
15 corporate actions are listed, the most recent entry being Annual General Meeting dated September 30, 2026, with a record date of September 30, 2026.
It is followed by Dividend dated September 23, 2026 and Extraordinary General Meeting dated August 22, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-09-30 | 2026-09-30 | Annual General Meeting | NA | -4.35% |
| 2026-09-23 | 2026-09-23 | Dividend | ₹ 0.67 /share | 11.63% |
| 2026-08-22 | 2026-08-22 | Extraordinary General Meeting | NA | 8.45% |
| 2026-08-07 | 2026-08-07 | Quarterly Result Announcement | NA | 2.69% |
| 2026-05-25 | 2026-05-25 | Quarterly Result Announcement | NA | 6.10% |
| 2026-02-05 | 2026-02-05 | Quarterly Result Announcement | NA | 6.98% |
| 2025-11-10 | 2025-11-10 | Quarterly Result Announcement | NA | -2.76% |
| 2025-09-12 | 2025-09-12 | Annual General Meeting | NA | 5.18% |
| 2025-09-04 | 2025-09-05 | Dividend | ₹ 0.67 /share | 14.14% |
| 2025-08-01 | 2025-08-01 | Quarterly Result Announcement | NA | 7.60% |
| 2025-05-20 | 2025-05-20 | Quarterly Result Announcement | NA | 6.23% |
| 2025-02-14 | 2025-02-14 | Quarterly Result Announcement | NA | -12.92% |
| 2024-10-25 | 2024-10-25 | Quarterly Result Announcement | NA | -7.92% |
| 2024-08-09 | 2024-08-09 | Bonus | 1:2 | 3.18% |
| 2024-07-23 | 2024-07-23 | Annual General Meeting | NA | 15.98% |
Gujarat Themis Biosyn Competitors Screener - Peer Stocks Comparison
Screen GUJTHEM competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 432,120 | 36.04 | 61,674 | 12.69% | 11,565 | 36.68 |
| Divis Laboratories | 245,532 | 84.24 | 11,067 | 13.95% | 2,568 | 51.70 |
| Torrent Pharmaceuticals | 181,333 | 84.71 | 13,886 | 20.34% | 2,138 | 41.12 |
| Zydus Life Science | 114,284 | 25.27 | 27,658 | 17.64% | 5,026 | 47.64 |
| Cipla | 108,576 | 32.50 | 29,045 | 2.24% | 3,870 | 34.78 |
| Laurus Labs | 107,198 | 98.20 | 6,868 | 22.01% | 890 | 58.70 |
| Mankind Pharma | 104,707 | 50.04 | 14,636 | 14.85% | 1,938 | 61.75 |
| Dr Reddys Laboratories | 100,679 | 32.41 | 35,059 | 3.90% | 4,158 | 53.84 |
| Aurobindo Pharma | 96,479 | 25.84 | 34,145 | 5.56% | 3,503 | 50.30 |
| Lupin | 92,885 | 16.82 | 29,039 | 26.75% | 5,356 | 31.59 |
Gujarat Themis Biosyn Company Announcements - News & Reports Screener
Screen GUJTHEM latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated October 3, 2026.
The next most recent announcements are dated October 2, 2026 and October 2, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-10-03 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-10-02 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-10-02 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-10-02 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-10-02 | Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association | - |
| 2026-10-02 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-09-25 | Closure of Trading Window | - |
| 2026-09-23 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-09-21 | Corrigendum To The Notice Of Annual General Meeting. | - |
| 2026-09-18 | Corporate Action-Fixed Record Date For Dividend For FY 2025-26 | - |
| 2026-09-18 | Announcement under Regulation 30 (LODR)-Updates on Acquisition | - |
| 2026-09-16 | Announcement under Regulation 30 (LODR)-Allotment | - |
| 2026-09-10 | Board Meeting Outcome for Outcome Of The Board Meeting Held On 10.09.2026 | - |
| 2026-09-08 | Addendum To The Notice Of 45Th Annual General Meeting (AGM) | - |
| 2026-09-07 | Board Meeting Intimation for Raising Funds Through Issue Of Non-Convertible Debentures By Way Of Private Placement. | - |
| 2026-09-07 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-09-04 | Business Responsibility and Sustainability Reporting (BRSR) | - |
| 2026-09-04 | Reg. 34 (1) Annual Report. | - |
| 2026-09-04 | Shareholders Meeting - AGM On 30.09.2026 | - |
| 2026-09-02 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹373.60, within a 52-week range of ₹226.90 to ₹469.90. The P/E ratio is 108.01 and the P/B ratio is 6.66, with earnings per unit of ₹4.28. Market capitalisation stands at ₹4,969.19 Cr and the dividend yield is 0.14%. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 5, 2026. This page covers 10 balance sheet periods, 3 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.